Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published August 27, 2012 | Published
Journal Article Open

miR-146a controls the resolution of T cell responses in mice

Abstract

T cell responses in mammals must be tightly regulated to both provide effective immune protection and avoid inflammation-induced pathology. NF-κB activation is a key signaling event induced by T cell receptor (TCR) stimulation. Dysregulation of NF-κB is associated with T cell–mediated inflammatory diseases and malignancies, highlighting the importance of negative feedback control of TCR-induced NF-κB activity. In this study we show that in mice, T cells lacking miR-146a are hyperactive in both acute antigenic responses and chronic inflammatory autoimmune responses. TCR-driven NF-κB activation up-regulates the expression of miR-146a, which in turn down-regulates NF-κB activity, at least partly through repressing the NF-κB signaling transducers TRAF6 and IRAK1. Thus, our results identify miR-146a as an important new member of the negative feedback loop that controls TCR signaling to NF-κB. Our findings also add microRNA to the list of regulators that control the resolution of T cell responses.

Additional Information

© 2012 Yang et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution– Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons. org/licenses/by-nc-sa/3.0/). Submitted: 19 October 2011. Accepted: 18 July 2012. We thank the California Institute of Technology animal facility for providing animal support, Shengli Hao for providing p50-/- mice, Pin Wang, Shengli Hao, and Michael Bethune for critical reading of this manuscript, and all members of the Baltimore group for insightful discussions. This work was supported by the National Institutes of Health P01 CA132681A and 5R01AI079243-02 grants. D. Baltimore is a director and chairman of the Scientific Advisory board of Regulus Therapeutics Inc., a biotech company developing miRNA-based drugs. Authors have no further conflicting interests.

Attached Files

Published - J_Exp_Med-2012-Yang-1655-70.pdf

Files

J_Exp_Med-2012-Yang-1655-70.pdf
Files (3.6 MB)
Name Size Download all
md5:eb081e690c8c8fe5c9d57961c2309180
3.6 MB Preview Download

Additional details

Created:
August 19, 2023
Modified:
October 18, 2023